Literature DB >> 24379905

The UVB cutaneous inflammatory pain model: a reproducibility study in healthy volunteers.

Carsten Dahl Mørch1, Parisa Gazerani1, Thomas A Nielsen1, Lars Arendt-Nielsen1.   

Abstract

BACKGROUND: The human ultraviolet-B (UVB) experimental pain model induces cutaneous neurogenic inflammation, involves hyperalgesia, and is widely used as a pharmacological screening pain model. AIM: To estimate the test-retest reliability of the UVB pain model by application of a comprehensive set of vasomotor and quantitative sensory assessment methods and to estimate sample sizes required for parallel or crossover pharmacological screening studies when this model is considered to be applied.
METHODS: The upper arms of 15 healthy male volunteers were UVB irradiated with three times the minimal erythema dose. Neurogenic inflammation was assessed by measuring erythema index, superficial blood flow and skin temperature at baseline, 1 day, 2 days and 3 days post irradiation. Sensory changes were assessed by brush stroke, von Frey hairs, pressure algometry, heat-evoked pain, stimulus response function to weight calibrated pin-prick stimulation, and the area of secondary hyperalgesia. The experiment was repeated with a two-week interval. Systematic bias, Coefficient of variation (CV), and intra-class correlation (ICC) were calculated within and between UVB irradiations. The sample sizes for parallel and crossover studies were calculated.
RESULTS: Neurogenic inflammation (erythema index) and primary hyperalgesia (pin-prick stimulation) remained significant for 3 days, and were highly reproducible within and between the UVB irradiations resulting of low sample sizes (4-26) in both parallel and crossover studies.
CONCLUSION: Based on sample size calculations, it is recommended to use the erythema index to assess neurogenic inflammation, and pin-prick stimulation for primary hyperalgesia for both parallel and crossover pharmacological screening studies.

Entities:  

Keywords:  Ultraviolet-B; primary hyperalgesia; quantitative sensory test; reproducibility; sample size; secondary hyperalgesia

Year:  2013        PMID: 24379905      PMCID: PMC3867698     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  32 in total

1.  A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects.

Authors:  Thomas Sycha; Burkhard Gustorff; Stephan Lehr; Adrian Tanew; Hans-Georg Eichler; Leopold Schmetterer
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

2.  A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model.

Authors:  Thomas Sycha; Doris Samal; Boris Chizh; Stephan Lehr; Burkhard Gustorff; Peter Schnider; Eduard Auff
Journal:  Anesth Analg       Date:  2006-02       Impact factor: 5.108

3.  Ultraviolet-B-induced mechanical hyperalgesia: A role for peripheral sensitisation.

Authors:  Thomas Bishop; Fabien Marchand; Antony R Young; Gary R Lewin; Stephen B McMahon
Journal:  Pain       Date:  2010-05-15       Impact factor: 6.961

Review 4.  Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine.

Authors:  G Atkinson; A M Nevill
Journal:  Sports Med       Date:  1998-10       Impact factor: 11.136

Review 5.  Power failure: why small sample size undermines the reliability of neuroscience.

Authors:  Katherine S Button; John P A Ioannidis; Claire Mokrysz; Brian A Nosek; Jonathan Flint; Emma S J Robinson; Marcus R Munafò
Journal:  Nat Rev Neurosci       Date:  2013-04-10       Impact factor: 34.870

6.  Lateral dominance, pain perception, and pain tolerance.

Authors:  A V Newton; J M Mumford
Journal:  J Dent Res       Date:  1972 Jul-Aug       Impact factor: 6.116

7.  Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man.

Authors:  A Bickel; S Dorfs; M Schmelz; C Forster; W Uhl; O H Handwerker
Journal:  Pain       Date:  1998-06       Impact factor: 6.961

8.  Ultraviolet-B induced inflammation of human skin: characterisation and comparison with traditional models of hyperalgesia.

Authors:  Thomas Bishop; Angela Ballard; Helen Holmes; Antony R Young; Stephen B McMahon
Journal:  Eur J Pain       Date:  2008-08-08       Impact factor: 3.931

9.  A comparison of two formulations of intradermal capsaicin as models of neuropathic pain in healthy volunteers.

Authors:  Helena Gustafsson; Johanna Akesson; Chai Li Lau; Desmond Williams; Lisa Miller; Sharon Yap; Paul Rolan
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

10.  Ultraviolet B dose-dependent inflammation in humans: a reflectance spectroscopic and laser Doppler flowmetric study using topical pharmacologic antagonists on irradiated skin.

Authors:  P H Andersen; K Abrams; H Maibach
Journal:  Photodermatol Photoimmunol Photomed       Date:  1992-02       Impact factor: 3.135

View more
  10 in total

1.  Sensory defunctionalization induced by 8% topical capsaicin treatment in a model of ultraviolet-B-induced cutaneous hyperalgesia.

Authors:  Silvia Lo Vecchio; Hjalte Holm Andersen; Jesper Elberling; Lars Arendt-Nielsen
Journal:  Exp Brain Res       Date:  2021-07-24       Impact factor: 1.972

2.  Is the conditioned pain modulation paradigm reliable? A test-retest assessment using the nociceptive withdrawal reflex.

Authors:  José A Biurrun Manresa; Raphael Fritsche; Pascal H Vuilleumier; Carmen Oehler; Carsten D Mørch; Lars Arendt-Nielsen; Ole K Andersen; Michele Curatolo
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

3.  Superoxide dismutase 1 inhibits alpha-melanocyte stimulating hormone and ultraviolet B-induced melanogenesis in murine skin.

Authors:  Chang Taek Oh; Dohyun Lee; Kyotan Koo; Jay Lee; Ho Sang Yoon; Yoo Mi Choi; Tae-Rin Kwon; Beom Joon Kim
Journal:  Ann Dermatol       Date:  2014-11-26       Impact factor: 1.444

4.  Effects of Salicornia-Based Skin Cream Application on Healthy Humans' Experimental Model of Pain and Itching.

Authors:  Rocco Giordano; Giulia Erica Aliotta; Anja Stokholm Johannesen; Dina Voetmann-Jensen; Frederikke Hillebrand Laustsen; Lasse Allermann Andersen; Aman Rezai; Malthe Fredsgaard; Silvia Lo Vecchio; Lars Arendt-Nielsen; Mette Hedegaard Thomsen; Allan Stensballe
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26

Review 5.  Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.

Authors:  Siro Luvisetto; Parisa Gazerani; Carlo Cianchetti; Flaminia Pavone
Journal:  Toxins (Basel)       Date:  2015-09-23       Impact factor: 4.546

6.  The Lancet Weight Determines Wheal Diameter in Response to Skin Prick Testing with Histamine.

Authors:  Hjalte H Andersen; Anna Charlotte Lundgaard; Anne S Petersen; Lise E Hauberg; Neha Sharma; Sofie D Hansen; Jesper Elberling; Lars Arendt-Nielsen
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

7.  Test-Retest Reliability of 10 Hz Conditioning Electrical Stimulation Inducing Long-Term Potentiation (LTP)-Like Pain Amplification in Humans.

Authors:  Weiwei Xia; Carsten Dahl Mørch; Ole Kæseler Andersen
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

8.  Topography of itch: evidence of distinct coding for pruriception in the trigeminal nerve.

Authors:  Hjalte H Andersen; Jesper Elberling; Silvia Lo Vecchio; Lars Arendt-Nielsen
Journal:  Itch (Phila)       Date:  2017-03-28

9.  The ultraviolet B inflammation model: Postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects.

Authors:  Pieter S Siebenga; Guido van Amerongen; Erica S Klaassen; Marieke L de Kam; Robert Rissmann; Geert Jan Groeneveld
Journal:  Eur J Pain       Date:  2019-02-01       Impact factor: 3.931

10.  A test-retest reliability study of assessing small cutaneous fibers by measuring current perception threshold with pin electrodes.

Authors:  Weiwei Xia; Han Fu; Haiying Liu; Fanqi Meng; Kaifeng Wang
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.